€ 8.3 bn
Q3/2016: €7.4 bn
€ 1481 m
Q3/2016: €1,373 m
€ 1129 m
Q3/2016: €1,071 m
Dec. 31, 2016: 232,873
€ 423 m
Q3/2016: €382 m
Earnings per Share2
1 In constant currency
2 Before acquisition-related expenses
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA; consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business
Stephan Sturm, Chairman of the Management Board
Fresenius Helios has presented the new Helios Science Prize for outstanding research by employees that contributes to improved treatment quality. The three winners all work at hospitals in Germany and were honored for their work in different areas of medicine. The prize, which comes with a cash award, went to Dr. Jitka Veldema of Helios Hospital Kipfenberg (for her work on stroke rehabilitation), Prof. Dr. Alexander Kreuter of Helios St. Elisabeth Hospital in Oberhausen (cancer diagnosis in HIV patients), and Dr. Patrick Weil of Helios University Hospital in Wuppertal (testicular cancer therapy).
Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.
Standard & Poor’s has revised Fresenius’ corporate credit outlook to positive from stable in late December 2017. The corporate credit rating was affirmed. Hence, Fresenius is now rated BBB- with positive outlook by Standard & Poor’s. Fresenius is rated investment grade by all of the three leading rating agencies Standard & Poor’s, Moody's and Fitch.
VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2017” at the World Spa Awards. Three VAMED Vitality World facilities – St. Martins Thermal Spa & Lodge and Thermal Spa Laa Hotel & Spa, both in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.
Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, will build a hospital in the city of Alcalá de Henares, just outside of Madrid. The approximately 11,000-square-meter (118,000-square-foot) facility will include 106 beds, four operating rooms and two delivery rooms. Quirónsalud will invest about €27 million in the new hospital. It is scheduled to open in 2019.
Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.
Fresenius Vamed has acquired a rehabilitation clinic in Switzerland, its third in the country. The clinic in Seewis has about 75 beds and specializes in heart disease, internal medicine and psychosomatic illnesses. Fresenius Vamed is now active in all major areas of rehabilitative medicine in Switzerland, with a clinic in Zihlschlacht that specializes in neurology and one in Dussnang specializing in orthopedics and geriatrics.
Fresenius Vamed has opened the Institute for Gender Medicine in cooperation with the Medical University of Vienna. This new research institute, in the Lower Austria town of Gars am Kamp, will focus on the different needs of female and male patients, for example in the interpretation of disease symptoms. Fresenius Vamed will be able to use the institute’s research findings to develop tailored treatment offerings in areas such as prevention and rehabilitation. The Institute for Gender Medicine complements initiatives for individualized medical care already being carried out by the VAMED International Medical Board and its approximately 650 physicians.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is undertaking a major expansion of University Hospital Quirónsalud Madrid. A new, 6,000-square-meter (almost 65,000-square-foot) wing scheduled for completion by next summer will add 52 new beds, bringing the hospital’s total to 288. The expansion will also include 25 doctors’ offices, nine resuscitation rooms and three delivery rooms, as well as two hybrid operating rooms that can be used both for conventional operations and for minimally invasive surgical procedures – so-called “keyhole surgery.” All expansion and modernization measures should be completed by the end of 2018. The total investment is about €31 million.
The price increase for hospital services in Germany has been set at 2.97% for 2018. This is in line with the level of past years.
Caspofungin, an antifungal medicine, expands the company's sterile injectable anti-infective portfolio.
The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.
Fresenius Helios continues to invest in the expansion and modernization of its hospitals and clinics. HELIOS Clinic Geesthacht, located just east of Hamburg, has opened an extension with 20 additional neurological rehabilitation places for young people. The investment in the specialist clinic for neurology and neurological rehabilitation is €4.6 million. In the state of Saxony, meanwhile, work has started on a new building for the emergency ward at HELIOS Hospital Leisnig. This €3.3 million project is scheduled for completion in autumn 2018.
Fresenius Helios is investing more than €18 million to expand the company’s hospital in the German town of Bad Saarow, about 25 kilometers (15 miles) east of Berlin. The project at HELIOS Hospital Bad Saarow includes construction of a new building that will add bed capacity to meet growing demand, and an expansion of the radiology department. The construction is scheduled for completion in spring 2019.
Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."
Azacitidine, a nucleoside metabolic inhibitor, expands the company's sterile injectable portfolio in oncology.
Vecuronium Bromide, a neuromuscular blocker, expands the company's sterile injectable portfolio in anesthesia.
HELIOS Hospital Wesermarsch has gone into operation in a newly built facility in the northern German town of Nordenham. The new hospital building has 120 patient beds, three operating rooms and a hybrid cardiac catheterization lab. Capacity can be increased to 235 beds, if needed. Fresenius Helios invested €36 million in the facility, which took about three years to build, with the County of Wesermarsch contributing an additional €10 million.
Clofarabine, a pediatric cancer product, expands the company's sterile injectable portfolio in oncology.
Following Fresenius’ announcement to acquire Akorn, Inc. and Merck KGaA’s biosimilars business, the rating agencies Standard & Poor’s (BBB-, stable), Moody’s (Baa3, stable) and Fitch (BBB-, stable) confirm the corporate credit ratings of Fresenius to be unaffected.
Quarterly Financial Report Q3 2017 (IFRS) (PDF, 350 KB)
Fresenius Factsheet Q3/2017 (PDF, 355 KB)
Investor Relations General Presentation (PDF, 833 KB)
Quarterly Financial Report Q2 2017 (IFRS) (PDF, 380 KB)
Quarterly Financial Report Q1 2017 (IFRS) (PDF, 295 KB)
Annual Report 2016 (U.S. GAAP) (PDF, 2.89 MB)
Consolidated Financial Statements / Management Report 2016 (IFRS) (PDF, 1.02 MB)
Quarterly Financial Report Q3 2016 (US-GAAP) (PDF, 337 KB)
Quarterly Financial Report Q3 2016 (IFRS) (PDF, 373 KB)
Quarterly Financial Report Q2 2016 (US-GAAP) (PDF, 369 KB)
Quarterly Financial Report Q2 2016 (IFRS) (PDF, 333 KB)
Quarterly Financial Report Q1 2016 (US-GAAP) (PDF, 830 KB)
Quarterly Financial Report Q1 2016 (IFRS) (PDF, 309 KB)
Annual Report 2015 (US-GAAP) (PDF, 3.18 MB)
Consolidated Financial Statements / Management Report 2015 (IFRS) (PDF, 1.02 MB)
Quarterly Financial Report Q3 2015 (US-GAAP) (PDF, 327 KB)
Quarterly Financial Report Q3 2015 (IFRS) (PDF, 358 KB)
Quarterly Financial Report Q2 2015 (US-GAAP) (PDF, 375 KB)